Share this video  

VJOncology is committed to improving our service to you

GU Cancers 2020 | KEYNOTE-866: pembrolizumab + chemotherapy for bladder cancer

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the KEYNOTE-866 trial (NCT03924856), which investigated perioperative pembrolizumab plus neoadjuvant chemotherapy versus perioperative placebo plus neoadjuvant chemotherapy for cisplatin-eligible muscle-invasive bladder cancer. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter